Beijing Saier Biological Pharmaceutical Co., Ltd.

Primary objective: To conduct a bioequivalence study on a single oral dose of dapagliflozin tablets (test preparation T, produced by Beijing Saier Biopharmaceutical Co., Ltd., specification: 10 mg/tablet) and dapagliflozin tablets (dapagliflozin tablets, reference preparation R, owned by AstraZeneca AB, produced by AstraZeneca Pharmaceuticals LP, trade name: Andatang®/FORXIGA®, specification: 10 mg/tablet) in healthy Chinese subjects under fasting state, to study the absorption rate and extent of the test preparation and the reference preparation in the human body, and to evaluate whether the test preparation and the reference preparation are bioequivalent. Secondary objective: To observe the safety of the test preparation dapagliflozin tablets and the reference preparation dapagliflozin tablets (Andatang®/FORXIGA®) in healthy subjects.

Primary objective: To conduct a bioequivalence study on a single oral dose of dapagliflozin tablets (test preparation T, produced by Beijing Saier Biopharmaceutical Co., Ltd., specification: 10 mg/tablet) and dapagliflozin tablets (dapagliflozin tablets, reference preparation R, owned by AstraZeneca AB and produced by AstraZeneca Pharmaceuticals LP, trade name: Andatang®/FORXIGA®, specification: 10 mg/tablet) in healthy Chinese subjects in the postprandial state, to study the absorption rate and extent of the test preparation and the reference preparation in the human body, and to evaluate whether the test preparation and the reference preparation are bioequivalent. Secondary objective: To observe the safety of the test preparation dapagliflozin tablets and the reference preparation dapagliflozin tablets (Andatang®/FORXIGA®) in healthy subjects.

Main objective: To investigate the absorption rate and extent of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets (Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, test preparation T, produced by Beijing Saier Biopharmaceutical Co., Ltd., provided by Beijing Saier Biopharmaceutical Co., Ltd., specifications: 10 mg/500 mg/tablet) and Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets (Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, reference preparation R, produced by AstraZeneca AB, trade name: Xigduo® XR, specifications: 10 mg/500 mg/tablet) in healthy study participants under fasting and fed conditions, and to evaluate whether the test preparation and the reference preparation are bioequivalent. Secondary objective: To observe the safety of the test formulation of dapagliflozin metformin extended-release tablets (IV) and the reference formulation of dapagliflozin metformin extended-release tablets (Xigduo® XR) in healthy study participants.